- Home
- RNA
as 07-26-2024 4:00pm EST
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.6B | IPO Year: | 2020 |
| Target Price: | $45.86 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.83 - $47.29 | Next Earning Date: | 08-06-2024 |
| Revenue: | $10,870,000 | Revenue Growth: | 12.50% |
| Revenue Growth (this year): | 36.57% | Revenue Growth (next year): | -17.84% |
Stock Insider Trading Activity of Avidity Biosciences Inc. (RNA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LEVIN ARTHUR A | RNA | Director | Jul 19 '24 | Sell | $45.01 | 5,000 | $225,069.00 | 14,830 | SEC Form 4 |
| Boyce Sarah | RNA | President and CEO | Jul 9 '24 | Sell | $39.93 | 28,000 | $1,118,082.00 | 205,043 | SEC Form 4 |
| LEVIN ARTHUR A | RNA | Director | Jun 20 '24 | Sell | $37.59 | 5,000 | $187,950.50 | 14,830 | SEC Form 4 |
| MacLean Michael F | RNA | Chief Financial Officer | Jun 17 '24 | Sell | $39.13 | 11,228 | $439,344.90 | 57,865 | SEC Form 4 |
| Boyce Sarah | RNA | President and CEO | Jun 17 '24 | Sell | $39.13 | 32,074 | $1,255,039.58 | 142,543 | SEC Form 4 |
| McCarthy Teresa | RNA | Chief Human Resources Officer | Jun 17 '24 | Sell | $39.13 | 9,864 | $385,972.40 | 32,171 | SEC Form 4 |
| MacLean Michael F | RNA | Chief Financial Officer | Jun 12 '24 | Sell | $35.72 | 104,245 | $3,723,141.45 | 44,093 | SEC Form 4 |
| LEVIN ARTHUR A | RNA | Director | Jun 12 '24 | Sell | $35.07 | 40,000 | $1,402,628.00 | 213,872 | SEC Form 4 |
| LEVIN ARTHUR A | RNA | Director | Jun 12 '24 | Sell | $40.08 | 60,000 | $2,404,782.00 | 153,872 | SEC Form 4 |
| Boyce Sarah | RNA | President and CEO | Jun 12 '24 | Sell | $35.73 | 100,000 | $3,573,020.00 | 112,117 | SEC Form 4 |
| Boyce Sarah | RNA | President and CEO | Jun 12 '24 | Sell | $40.08 | 164,233 | $6,581,801.71 | 112,117 | SEC Form 4 |
| Boyce Sarah | RNA | President and CEO | Jun 12 '24 | Sell | $40.08 | 35,767 | $1,433,484.13 | 112,117 | SEC Form 4 |
| Boyce Sarah | RNA | President and CEO | Jun 4 '24 | Sell | $27.42 | 28,000 | $767,779.60 | 112,117 | SEC Form 4 |
| LEVIN ARTHUR A | RNA | Director | May 20 '24 | Sell | $29.90 | 5,000 | $149,481.00 | 14,830 | SEC Form 4 |
| MacLean Michael F | RNA | Chief Financial Officer | May 14 '24 | Sell | $28.28 | 75,000 | $2,121,045.00 | 44,093 | SEC Form 4 |
| Boyce Sarah | RNA | President and CEO | May 7 '24 | Sell | $25.54 | 28,000 | $715,050.00 | 112,117 | SEC Form 4 |
| LEVIN ARTHUR A | RNA | Director | Apr 19 '24 | Sell | $22.82 | 5,000 | $114,123.00 | 14,830 | SEC Form 4 |
| LEVIN ARTHUR A | RNA | Director | Apr 3 '24 | Sell | $27.11 | 20,000 | $542,214.00 | 253,872 | SEC Form 4 |
| Boyce Sarah | RNA | President and CEO | Apr 2 '24 | Sell | $26.25 | 28,000 | $734,918.80 | 112,117 | SEC Form 4 |
| LEVIN ARTHUR A | RNA | Director | Mar 19 '24 | Sell | $23.97 | 5,000 | $119,847.50 | 14,830 | SEC Form 4 |
| MacLean Michael F | RNA | Chief Financial Officer | Mar 13 '24 | Sell | $24.52 | 40,000 | $980,760.00 | 44,093 | SEC Form 4 |
| LEVIN ARTHUR A | RNA | Director | Mar 12 '24 | Sell | $22.04 | 25,000 | $550,915.00 | 17,471 | SEC Form 4 |
| LEVIN ARTHUR A | RNA | Director | Mar 12 '24 | Sell | $22.00 | 2,641 | $58,102.00 | 14,830 | SEC Form 4 |
| Boyce Sarah | RNA | President and CEO | Mar 8 '24 | Sell | $21.39 | 84,000 | $1,796,709.60 | 112,117 | SEC Form 4 |
| Boyce Sarah | RNA | President and CEO | Mar 8 '24 | Sell | $22.63 | 28,000 | $633,682.00 | 112,117 | SEC Form 4 |
Latest Avidity Biosciences Inc. News
RNA Breaking Stock News: Dive into RNA Ticker-Specific Updates for Smart Investing
Motley Fool
4 days ago
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
PR Newswire
4 days ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Clinical Trials Arena
24 days ago
Avidity’s FSHD drug del-brax shows promise in Phase I/II trial
PR Newswire
a month ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
Avidity Biosciences Insider Sold Shares Worth $1,255,040, According to a Recent SEC Filing
PR Newswire
a month ago
Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day
Simply Wall St.
a month ago
Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)
PR Newswire
a month ago
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Compare RNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNA Avidity Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.